Form 4: Director Gregory Lucier Increases Stake in Maravai

Director Gregory T. Lucier acquired 46,293 shares of Maravai LifeSciences Holdings, Inc. through a restricted stock unit grant.

Summary

• Director Gregory T. Lucier was granted 46,293 restricted stock units (RSUs) of Class A Common Stock.
• The grant occurred on May 26, 2026, at a valuation of $4.38 per share.
• Following this transaction, the director's direct beneficial ownership increased to 201,416 shares.
• The director maintains an additional 109,784 shares held indirectly through a family partnership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine disclosure of director compensation that does not signal a change in company strategy or financial health.

Positives

• Director alignment with shareholder interests through increased equity ownership.
• Standard equity-based compensation structure under the 2020 Omnibus Incentive Plan.

Negatives

• None identified in this filing.

Risks

• Vesting of equity is subject to the passage of time or the occurrence of the 2027 annual meeting, which could be impacted by future corporate events.

Future Outlook

The RSUs vest in full on the earlier of one year from the grant date or the date of the 2027 annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the life sciences sector to ensure long-term alignment between board members and company performance.

Comparison to Industry Standards

• The use of RSU grants for board compensation is consistent with standard corporate governance practices for mid-cap life sciences companies.

Stakeholder Impact

• Increased alignment between the board of directors and shareholders.

Next Steps

• Vesting of the 46,293 RSUs in 2027.

Key Dates

Keywords

Maravai LifeSciences, MRVI, Insider Trading, Form 4, Equity Compensation, Gregory Lucier